Summit Therapeutics (NASDAQ:SMMT - Get Free Report) released its earnings results on Monday. The company reported ($0.08) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.08), Zacks reports. The business had revenue of $0.20 million for the quarter.
Summit Therapeutics Trading Up 1.0 %
SMMT stock traded up $0.19 during trading on Thursday, hitting $18.49. 2,200,069 shares of the company's stock were exchanged, compared to its average volume of 2,497,372. The business has a 50-day moving average price of $19.93 and a two-hundred day moving average price of $19.19. The stock has a market capitalization of $13.64 billion, a price-to-earnings ratio of -66.03 and a beta of -0.88. Summit Therapeutics has a 52-week low of $2.10 and a 52-week high of $33.89.
Analyst Ratings Changes
Several analysts have recently issued reports on the company. StockNews.com cut Summit Therapeutics from a "hold" rating to a "sell" rating in a research note on Tuesday. Truist Financial started coverage on Summit Therapeutics in a research report on Wednesday, January 8th. They issued a "buy" rating and a $35.00 price target on the stock. JMP Securities began coverage on Summit Therapeutics in a research note on Monday, November 4th. They issued a "market outperform" rating and a $32.00 price objective for the company. Jefferies Financial Group initiated coverage on shares of Summit Therapeutics in a research note on Friday, December 6th. They set a "buy" rating and a $31.00 target price on the stock. Finally, Wells Fargo & Company began coverage on shares of Summit Therapeutics in a research note on Wednesday, December 11th. They issued an "overweight" rating and a $30.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, Summit Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $33.57.
View Our Latest Research Report on SMMT
About Summit Therapeutics
(
Get Free Report)
Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
Further Reading
Before you consider Summit Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Summit Therapeutics wasn't on the list.
While Summit Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
